Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging
- 276 Downloads
The purpose of this study was to design and evaluate a novel platform for labelling of Affibody molecules, enabling both recombinant and synthetic production and site-specific labelling with 99mTc or trivalent radiometals.
The HER2-specific Affibody molecule PEP05352 was made by peptide synthesis. The chelator sequence SECG (serine-glutamic acid-cysteine-glycine) was anchored on the C-terminal to allow 99mTc labelling. The cysteine can alternatively serve as a conjugation site of the chelator DOTA for indium labelling. The resulting 99mTc- and 111In-labelled Affibody molecules were evaluated both in vitro and in vivo.
Both conjugates retained their capacity to bind to HER2 receptors in vitro and in vivo. The tumour to blood ratio in LS174T xenografts was 30 at 4 h post-injection for both conjugates. Biodistribution data showed that the 99mTc-labelled Affibody molecule had a fourfold lower kidney accumulation compared with the 111In-labelled Affibody molecule while the accumulation in other organs was similar. Gamma camera imaging of the conjugates could clearly visualise the tumours 4 h after injection.
Incorporation of the C-terminal SECG sequence in Affibody molecules provides a general multifunctional platform for site-specific labelling with different nuclides (technetium, indium, gallium, cobalt or yttrium) and for a flexible production (chemical synthesis or recombinant).
KeywordsHER2 Affibody molecules Peptide synthesis Imaging
This research was financially supported by grant from the Swedish Cancer Society (Cancerfonden).
- 2.Tran T, Tolmachev V. Affibody molecules, a new class of targeting agents for molecular imaging. In: Chen X, editor. Recent advances of bioconjugation chemistry in molecular imaging. Kerala, India: Research Signpost; 2008. p. 1–17.Google Scholar
- 4.Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of 124I-labelled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009;50:417–25. doi: 10.2967/jnumed.108.057919.CrossRefPubMedGoogle Scholar
- 8.Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66–73. doi: 10.1002/cncr.11476.CrossRefPubMedGoogle Scholar
- 18.Engfeldt T, Orlova A, Tran T, Bruskin A, Widström C, Karlström AE, et al. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34:722–33. doi: 10.1007/s00259-006-0266-4.CrossRefPubMedGoogle Scholar
- 24.Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008–18. doi: 10.1007/s00259-007-0658-0.CrossRefPubMedGoogle Scholar
- 29.Tanaka K, Fukase K. PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics. Org Biomol Chem 2008;6:815–28. doi: 10.1039/b718157b.CrossRefPubMedGoogle Scholar
- 33.Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200–6. doi: 10.1158/0008-5472.CAN-03-2382.CrossRefPubMedGoogle Scholar